- Home
- GHY vs VNDA Comparison
GHY vs VNDA Comparison
Compare GHY & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GHY | VNDA |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 509.1M | 425.5M |
| IPO Year | N/A | 2006 |
Fundamental Metrics
Financial Performance| Metric | GHY | VNDA |
|---|---|---|
| Price | $12.60 | $7.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $13.63 |
| AVG Volume (30 Days) | 184.8K | ★ 2.9M |
| Earning Date | 01-01-0001 | 02-12-2026 |
| Dividend Yield | ★ 10.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $212,074,000.00 |
| Revenue This Year | N/A | $12.01 |
| Revenue Next Year | N/A | $21.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.12 |
| 52 Week Low | $10.24 | $3.81 |
| 52 Week High | $11.92 | $9.60 |
Technical Indicators
Market Signals| Indicator | GHY | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 63.31 | 57.10 |
| Support Level | $12.30 | $7.12 |
| Resistance Level | $12.55 | $8.55 |
| Average True Range (ATR) | 0.08 | 0.48 |
| MACD | 0.03 | -0.10 |
| Stochastic Oscillator | 82.19 | 32.11 |
Price Performance
Historical ComparisonAbout GHY PGIM Global High Yield Fund Inc.
PGIM Global High Yield Fund, Inc is a diversified, closed-end management investment company. The fund's investment objective is to provide a high level of current income. The fund seeks to provide a high level of current income by investing in higher-rated, below-investment-grade fixed income instruments of issuers located around the world, including emerging markets.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.